{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T05:18:18Z","timestamp":1792732698070,"version":"4.5.0"},"reference-count":43,"publisher":"Massachusetts Medical Society","issue":"2","license":[{"start":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T00:00:00Z","timestamp":1736380800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.nejmgroup.org\/legal\/terms-of-use.htm"}],"funder":[{"DOI":"10.13039\/100014931","name":"Arrowhead Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014931","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["N Engl J Med"],"published-print":{"date-parts":[[2025,1,9]]},"DOI":"10.1056\/nejmoa2409368","type":"journal-article","created":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T06:36:17Z","timestamp":1725258977000},"page":"127-137","source":"Crossref","is-referenced-by-count":176,"title":["Plozasiran for Managing Persistent Chylomicronemia and Pancreatitis Risk"],"prefix":"10.1056","volume":"392","author":[{"given":"Gerald F.","family":"Watts","sequence":"first","affiliation":[{"name":"From the School of Medicine, University of Western Australia, and the Department of Cardiology, Royal Perth Hospital \u2014 both in Perth, Australia (G.F.W.); the Metabolism and Lipids Program, Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai (R.S.R.), and New York University (NYU) Grossman School of Medicine, NYU Langone Health (I.J.G) \u2014 both in New York; Robarts Research Institute, London, ON (R.A.H.), and the Department of Medicine, McGill University, and the Genetic Dyslipidemia Clinic, Montreal Clinical Research Institute (A.B.) and Universit\u00e9 de Montr\u00e9al and ECOGENE-21 (D.G.), Montreal \u2014 all in Canada; Sorbonne University, INSERM UMR1166, Lipidology and Cardiovascular Prevention Unit, Department of Nutrition, Piti\u00e9\u2013Salp\u00eatri\u00e8re Hospital, Assistance Publique\u2013H\u00f4pitaux de Paris, Paris (A.G.); the Department of Endocrinology, University Hospitals Leuven\u2013KU Leuven, Leuven, Belgium (A.M.); and Arrowhead Pharmaceuticals, Pasadena (R.Z., M.M., J.H.), and Stanford University, Palo Alto (N...."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert S.","family":"Rosenson","sequence":"additional","affiliation":[{"name":"From the School of Medicine, University of Western Australia, and the Department of Cardiology, Royal Perth Hospital \u2014 both in Perth, Australia (G.F.W.); the Metabolism and Lipids Program, Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai (R.S.R.), and New York University (NYU) Grossman School of Medicine, NYU Langone Health (I.J.G) \u2014 both in New York; Robarts Research Institute, London, ON (R.A.H.), and the Department of Medicine, McGill University, and the Genetic Dyslipidemia Clinic, Montreal Clinical Research Institute (A.B.) and Universit\u00e9 de Montr\u00e9al and ECOGENE-21 (D.G.), Montreal \u2014 all in Canada; Sorbonne University, INSERM UMR1166, Lipidology and Cardiovascular Prevention Unit, Department of Nutrition, Piti\u00e9\u2013Salp\u00eatri\u00e8re Hospital, Assistance Publique\u2013H\u00f4pitaux de Paris, Paris (A.G.); the Department of Endocrinology, University Hospitals Leuven\u2013KU Leuven, Leuven, Belgium (A.M.); and Arrowhead Pharmaceuticals, Pasadena (R.Z., M.M., J.H.), and Stanford University, Palo Alto (N...."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Hegele","sequence":"additional","affiliation":[{"name":"From the School of Medicine, University of Western Australia, and the Department of Cardiology, Royal Perth Hospital \u2014 both in Perth, Australia (G.F.W.); the Metabolism and Lipids Program, Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai (R.S.R.), and New York University (NYU) Grossman School of Medicine, NYU Langone Health (I.J.G) \u2014 both in New York; Robarts Research Institute, London, ON (R.A.H.), and the Department of Medicine, McGill University, and the Genetic Dyslipidemia Clinic, Montreal Clinical Research Institute (A.B.) and Universit\u00e9 de Montr\u00e9al and ECOGENE-21 (D.G.), Montreal \u2014 all in Canada; Sorbonne University, INSERM UMR1166, Lipidology and Cardiovascular Prevention Unit, Department of Nutrition, Piti\u00e9\u2013Salp\u00eatri\u00e8re Hospital, Assistance Publique\u2013H\u00f4pitaux de Paris, Paris (A.G.); the Department of Endocrinology, University Hospitals Leuven\u2013KU Leuven, Leuven, Belgium (A.M.); and Arrowhead Pharmaceuticals, Pasadena (R.Z., M.M., J.H.), and Stanford University, Palo Alto (N...."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ira J.","family":"Goldberg","sequence":"additional","affiliation":[{"name":"From the School of Medicine, University of Western Australia, and the Department of Cardiology, Royal Perth Hospital \u2014 both in Perth, Australia (G.F.W.); the Metabolism and Lipids Program, Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai (R.S.R.), and New York University (NYU) Grossman School of Medicine, NYU Langone Health (I.J.G) \u2014 both in New York; Robarts Research Institute, London, ON (R.A.H.), and the Department of Medicine, McGill University, and the Genetic Dyslipidemia Clinic, Montreal Clinical Research Institute (A.B.) and Universit\u00e9 de Montr\u00e9al and ECOGENE-21 (D.G.), Montreal \u2014 all in Canada; Sorbonne University, INSERM UMR1166, Lipidology and Cardiovascular Prevention Unit, Department of Nutrition, Piti\u00e9\u2013Salp\u00eatri\u00e8re Hospital, Assistance Publique\u2013H\u00f4pitaux de Paris, Paris (A.G.); the Department of Endocrinology, University Hospitals Leuven\u2013KU Leuven, Leuven, Belgium (A.M.); and Arrowhead Pharmaceuticals, Pasadena (R.Z., M.M., J.H.), and Stanford University, Palo Alto (N...."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Gallo","sequence":"additional","affiliation":[{"name":"From the School of Medicine, University of Western Australia, and the Department of Cardiology, Royal Perth Hospital \u2014 both in Perth, Australia (G.F.W.); the Metabolism and Lipids Program, Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai (R.S.R.), and New York University (NYU) Grossman School of Medicine, NYU Langone Health (I.J.G) \u2014 both in New York; Robarts Research Institute, London, ON (R.A.H.), and the Department of Medicine, McGill University, and the Genetic Dyslipidemia Clinic, Montreal Clinical Research Institute (A.B.) and Universit\u00e9 de Montr\u00e9al and ECOGENE-21 (D.G.), Montreal \u2014 all in Canada; Sorbonne University, INSERM UMR1166, Lipidology and Cardiovascular Prevention Unit, Department of Nutrition, Piti\u00e9\u2013Salp\u00eatri\u00e8re Hospital, Assistance Publique\u2013H\u00f4pitaux de Paris, Paris (A.G.); the Department of Endocrinology, University Hospitals Leuven\u2013KU Leuven, Leuven, Belgium (A.M.); and Arrowhead Pharmaceuticals, Pasadena (R.Z., M.M., J.H.), and Stanford University, Palo Alto (N...."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Mertens","sequence":"additional","affiliation":[{"name":"From the School of Medicine, University of Western Australia, and the Department of Cardiology, Royal Perth Hospital \u2014 both in Perth, Australia (G.F.W.); the Metabolism and Lipids Program, Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai (R.S.R.), and New York University (NYU) Grossman School of Medicine, NYU Langone Health (I.J.G) \u2014 both in New York; Robarts Research Institute, London, ON (R.A.H.), and the Department of Medicine, McGill University, and the Genetic Dyslipidemia Clinic, Montreal Clinical Research Institute (A.B.) and Universit\u00e9 de Montr\u00e9al and ECOGENE-21 (D.G.), Montreal \u2014 all in Canada; Sorbonne University, INSERM UMR1166, Lipidology and Cardiovascular Prevention Unit, Department of Nutrition, Piti\u00e9\u2013Salp\u00eatri\u00e8re Hospital, Assistance Publique\u2013H\u00f4pitaux de Paris, Paris (A.G.); the Department of Endocrinology, University Hospitals Leuven\u2013KU Leuven, Leuven, Belgium (A.M.); and Arrowhead Pharmaceuticals, Pasadena (R.Z., M.M., J.H.), and Stanford University, Palo Alto (N...."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"Baass","sequence":"additional","affiliation":[{"name":"From the School of Medicine, University of Western Australia, and the Department of Cardiology, Royal Perth Hospital \u2014 both in Perth, Australia (G.F.W.); the Metabolism and Lipids Program, Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai (R.S.R.), and New York University (NYU) Grossman School of Medicine, NYU Langone Health (I.J.G) \u2014 both in New York; Robarts Research Institute, London, ON (R.A.H.), and the Department of Medicine, McGill University, and the Genetic Dyslipidemia Clinic, Montreal Clinical Research Institute (A.B.) and Universit\u00e9 de Montr\u00e9al and ECOGENE-21 (D.G.), Montreal \u2014 all in Canada; Sorbonne University, INSERM UMR1166, Lipidology and Cardiovascular Prevention Unit, Department of Nutrition, Piti\u00e9\u2013Salp\u00eatri\u00e8re Hospital, Assistance Publique\u2013H\u00f4pitaux de Paris, Paris (A.G.); the Department of Endocrinology, University Hospitals Leuven\u2013KU Leuven, Leuven, Belgium (A.M.); and Arrowhead Pharmaceuticals, Pasadena (R.Z., M.M., J.H.), and Stanford University, Palo Alto (N...."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Zhou","sequence":"additional","affiliation":[{"name":"From the School of Medicine, University of Western Australia, and the Department of Cardiology, Royal Perth Hospital \u2014 both in Perth, Australia (G.F.W.); the Metabolism and Lipids Program, Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai (R.S.R.), and New York University (NYU) Grossman School of Medicine, NYU Langone Health (I.J.G) \u2014 both in New York; Robarts Research Institute, London, ON (R.A.H.), and the Department of Medicine, McGill University, and the Genetic Dyslipidemia Clinic, Montreal Clinical Research Institute (A.B.) and Universit\u00e9 de Montr\u00e9al and ECOGENE-21 (D.G.), Montreal \u2014 all in Canada; Sorbonne University, INSERM UMR1166, Lipidology and Cardiovascular Prevention Unit, Department of Nutrition, Piti\u00e9\u2013Salp\u00eatri\u00e8re Hospital, Assistance Publique\u2013H\u00f4pitaux de Paris, Paris (A.G.); the Department of Endocrinology, University Hospitals Leuven\u2013KU Leuven, Leuven, Belgium (A.M.); and Arrowhead Pharmaceuticals, Pasadena (R.Z., M.M., J.H.), and Stanford University, Palo Alto (N...."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma\u2019an","family":"Muhsin","sequence":"additional","affiliation":[{"name":"From the School of Medicine, University of Western Australia, and the Department of Cardiology, Royal Perth Hospital \u2014 both in Perth, Australia (G.F.W.); the Metabolism and Lipids Program, Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai (R.S.R.), and New York University (NYU) Grossman School of Medicine, NYU Langone Health (I.J.G) \u2014 both in New York; Robarts Research Institute, London, ON (R.A.H.), and the Department of Medicine, McGill University, and the Genetic Dyslipidemia Clinic, Montreal Clinical Research Institute (A.B.) and Universit\u00e9 de Montr\u00e9al and ECOGENE-21 (D.G.), Montreal \u2014 all in Canada; Sorbonne University, INSERM UMR1166, Lipidology and Cardiovascular Prevention Unit, Department of Nutrition, Piti\u00e9\u2013Salp\u00eatri\u00e8re Hospital, Assistance Publique\u2013H\u00f4pitaux de Paris, Paris (A.G.); the Department of Endocrinology, University Hospitals Leuven\u2013KU Leuven, Leuven, Belgium (A.M.); and Arrowhead Pharmaceuticals, Pasadena (R.Z., M.M., J.H.), and Stanford University, Palo Alto (N...."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Hellawell","sequence":"additional","affiliation":[{"name":"From the School of Medicine, University of Western Australia, and the Department of Cardiology, Royal Perth Hospital \u2014 both in Perth, Australia (G.F.W.); the Metabolism and Lipids Program, Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai (R.S.R.), and New York University (NYU) Grossman School of Medicine, NYU Langone Health (I.J.G) \u2014 both in New York; Robarts Research Institute, London, ON (R.A.H.), and the Department of Medicine, McGill University, and the Genetic Dyslipidemia Clinic, Montreal Clinical Research Institute (A.B.) and Universit\u00e9 de Montr\u00e9al and ECOGENE-21 (D.G.), Montreal \u2014 all in Canada; Sorbonne University, INSERM UMR1166, Lipidology and Cardiovascular Prevention Unit, Department of Nutrition, Piti\u00e9\u2013Salp\u00eatri\u00e8re Hospital, Assistance Publique\u2013H\u00f4pitaux de Paris, Paris (A.G.); the Department of Endocrinology, University Hospitals Leuven\u2013KU Leuven, Leuven, Belgium (A.M.); and Arrowhead Pharmaceuticals, Pasadena (R.Z., M.M., J.H.), and Stanford University, Palo Alto (N...."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas J.","family":"Leeper","sequence":"additional","affiliation":[{"name":"From the School of Medicine, University of Western Australia, and the Department of Cardiology, Royal Perth Hospital \u2014 both in Perth, Australia (G.F.W.); the Metabolism and Lipids Program, Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai (R.S.R.), and New York University (NYU) Grossman School of Medicine, NYU Langone Health (I.J.G) \u2014 both in New York; Robarts Research Institute, London, ON (R.A.H.), and the Department of Medicine, McGill University, and the Genetic Dyslipidemia Clinic, Montreal Clinical Research Institute (A.B.) and Universit\u00e9 de Montr\u00e9al and ECOGENE-21 (D.G.), Montreal \u2014 all in Canada; Sorbonne University, INSERM UMR1166, Lipidology and Cardiovascular Prevention Unit, Department of Nutrition, Piti\u00e9\u2013Salp\u00eatri\u00e8re Hospital, Assistance Publique\u2013H\u00f4pitaux de Paris, Paris (A.G.); the Department of Endocrinology, University Hospitals Leuven\u2013KU Leuven, Leuven, Belgium (A.M.); and Arrowhead Pharmaceuticals, Pasadena (R.Z., M.M., J.H.), and Stanford University, Palo Alto (N...."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Gaudet","sequence":"additional","affiliation":[{"name":"From the School of Medicine, University of Western Australia, and the Department of Cardiology, Royal Perth Hospital \u2014 both in Perth, Australia (G.F.W.); the Metabolism and Lipids Program, Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai (R.S.R.), and New York University (NYU) Grossman School of Medicine, NYU Langone Health (I.J.G) \u2014 both in New York; Robarts Research Institute, London, ON (R.A.H.), and the Department of Medicine, McGill University, and the Genetic Dyslipidemia Clinic, Montreal Clinical Research Institute (A.B.) and Universit\u00e9 de Montr\u00e9al and ECOGENE-21 (D.G.), Montreal \u2014 all in Canada; Sorbonne University, INSERM UMR1166, Lipidology and Cardiovascular Prevention Unit, Department of Nutrition, Piti\u00e9\u2013Salp\u00eatri\u00e8re Hospital, Assistance Publique\u2013H\u00f4pitaux de Paris, Paris (A.G.); the Department of Endocrinology, University Hospitals Leuven\u2013KU Leuven, Leuven, Belgium (A.M.); and Arrowhead Pharmaceuticals, Pasadena (R.Z., M.M., J.H.), and Stanford University, Palo Alto (N...."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"150","reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehz785"},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/joim.13016"},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.1080\/14779072.2017.1372193"},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2018.06.814"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.7326\/M19-0203"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(21)00046-2"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.00455"},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2021.06.011"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2015.26"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe2402653"},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.mcg.0000436438.60145.5a"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI107334"},{"key":"e_1_3_5_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvad177"},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2020.08.016"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.1080\/17446651.2024.2365787"},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200325"},{"key":"e_1_3_5_18_2","doi-asserted-by":"publisher","DOI":"10.4158\/EP-2018-0157"},{"key":"e_1_3_5_19_2","doi-asserted-by":"publisher","DOI":"10.1177\/2047487319888054"},{"key":"e_1_3_5_20_2","unstructured":"Food and Drug Administration. Briefing document. Endocrinologic and Metabolic Drugs Advisory Committee Meeting. May 10 2018 (https:\/\/wayback.archive-it.org\/7993\/20201227021311\/https:\/\/www.fda.gov\/media\/113306\/download)."},{"key":"e_1_3_5_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2020.01.014"},{"key":"e_1_3_5_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2015.02.003"},{"key":"e_1_3_5_23_2","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2012-302779"},{"key":"e_1_3_5_24_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2404143"},{"key":"e_1_3_5_25_2","doi-asserted-by":"publisher","DOI":"10.1097\/MED.0000000000000857"},{"key":"e_1_3_5_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2023.05.008"},{"key":"e_1_3_5_27_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2400201"},{"key":"e_1_3_5_28_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1715944"},{"key":"e_1_3_5_29_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinchem\/hvad094"},{"key":"e_1_3_5_30_2","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2015.261"},{"key":"e_1_3_5_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2016.02.019"},{"key":"e_1_3_5_32_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehz455"},{"key":"e_1_3_5_33_2","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.114.305172"},{"key":"e_1_3_5_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2010.11.008"},{"key":"e_1_3_5_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(19)30264-5"},{"key":"e_1_3_5_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2020.04.011"},{"key":"e_1_3_5_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2018.12.019"},{"key":"e_1_3_5_38_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11883-021-00962-z"},{"key":"e_1_3_5_39_2","doi-asserted-by":"publisher","DOI":"10.1097\/MED.0000000000000136"},{"key":"e_1_3_5_40_2","first-page":"105","article-title":"Severe hypertriglyceridaemia as a result of familial chylomicronaemia: the Cape Town experience.","volume":"98","author":"Pouwels ED","year":"2008","unstructured":"Pouwels ED, Blom DJ, Firth JC, Henderson HE, Marais AD. Severe hypertriglyceridaemia as a result of familial chylomicronaemia: the Cape Town experience. S Afr Med J 2008;98:105-108.18350203","journal-title":"S Afr Med J"},{"key":"e_1_3_5_41_2","doi-asserted-by":"publisher","DOI":"10.1080\/14779072.2017.1311786"},{"key":"e_1_3_5_42_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab551"},{"key":"e_1_3_5_43_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000001184"},{"key":"e_1_3_5_44_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaa172"}],"container-title":["New England Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nejm.org\/doi\/pdf\/10.1056\/NEJMoa2409368","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T18:32:18Z","timestamp":1749666738000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.nejm.org\/doi\/10.1056\/NEJMoa2409368"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,9]]},"references-count":43,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,1,9]]}},"alternative-id":["10.1056\/NEJMoa2409368"],"URL":"https:\/\/doi.org\/10.1056\/nejmoa2409368","relation":{},"ISSN":["0028-4793","1533-4406"],"issn-type":[{"value":"0028-4793","type":"print"},{"value":"1533-4406","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,9]]}}}